NEW YORK (GenomeWeb News) – Upstream Biosciences yesterday said it has signed an option to buy Pacific Pharma Technologies, a company focused on drug development for parasitic diseases.
 
Upstream Biosciences, which develops genetic diagnostics for cancer and for predicting drug responses, said the agreement gives it an exclusive 3-month option to negotiate terms of the acquisition.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.